Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)

10/19/2021 | 08:34am EST

Item 8.01 Other Events.

On October 19, 2021, VYNE Therapeutics Inc. issued a press release entitled "VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


The following exhibit is being filed herewith.


Exhibit No.            Description

  99.1                   Press Release, dated October 19, 2021.

                       Cover Page Interactive Data File (embedded within the Inline XBRL
104                    document)

© Edgar Online, source Glimpses

All news about VYNE THERAPEUTICS INC.
11/18VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Confer..
AQ
11/10VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/10VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/10VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up..
PU
11/10VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
11/10VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up..
AQ
11/10Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $4.1M, vs. Street Est of $4.76..
MT
11/10Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Loss $-0.36, vs. Street Est of $-0.3..
MT
11/10NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/04Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass a..
PU
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 16,7 M - -
Net income 2021 -68,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,75x
Yield 2021 -
Capitalization 55,1 M 55,1 M -
Capi. / Sales 2021 3,31x
Capi. / Sales 2022 7,90x
Nbr of Employees 106
Free-Float 92,6%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,03 $
Average target price 5,00 $
Spread / Average Target 385%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-83.70%55
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049